Organovo (NASDAQ:ONVO) Now Covered by StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Organovo (NASDAQ:ONVO) in a research note issued on Saturday. The brokerage set a “sell” rating on the medical research company’s stock.

Organovo Stock Performance

Shares of NASDAQ ONVO opened at $1.03 on Friday. The company has a market cap of $10.34 million, a PE ratio of -0.47 and a beta of 0.87. The firm’s 50 day moving average price is $1.04 and its 200-day moving average price is $1.11. Organovo has a 52-week low of $0.89 and a 52-week high of $2.05.

Organovo (NASDAQ:ONVO) last posted its quarterly earnings results on Thursday, February 8th. The medical research company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.01. The business had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.08 million. On average, analysts forecast that Organovo will post -1.74 earnings per share for the current fiscal year.

About Organovo

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.